Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Molecular Cancer Therapeutics|September 3, 2010
Discovery and characterization of novel mutant FLT3 kinase inhibitorsEllen Weisberg, Hwan Geun Choi, Rosemary Barrett, et al.The Lancet. Neurology|March 15, 2011
Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomesAlasdair J Coles, Edward Fox, Anton Vladic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.Proceedings of the National Academy of Sciences of the United States of America|May 4, 2006
XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient miceCatherine T Yan, Dhruv Kaushal, Michael Murphy, et al.Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.The New England Journal of Medicine|August 24, 2022
Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisLawrence Steinman, Edward Fox, Hans-Peter Hartung, et al.British Journal of Haematology|February 18, 2009
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu, Zachary R Hunter, Lian Xu, et al.EFSA Journal. European Food Safety Authority|January 22, 2024
Persistence of microbiological hazards in food and feed production and processing environments, Konstantinos Koutsoumanis, Ana Allende, et al.Pageof 7